EU First for PROPEL® Contour in Chronic Rhinosinusitis Following Frontal Sinus Surgery

Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany has become the first hospital outside the United States to offer Intersect ENT’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic sinus surgery (FESS).

Background

Intersect ENT®, Inc., is a global ear, nose and throat (ENT) medical technology company.

Intersect ENT’s PROPEL Contour is a drug-eluting, bioabsorbable sinus implant that is placed in the frontal sinus following sinus surgery. PROPEL Contour incorporates a unique hourglass design that conforms to the sinus openings. It delivers an advanced corticosteroid with anti-inflammatory properties and mechanical support to help improve surgical outcomes. PROPEL Contour is clinically proven to reduce the need for additional interventions after sinus surgery by 65 percent. It is the company’s third localized drug delivery implant, completing the PROPEL family of drug-eluting, bioabsorbable implants now available to ENT specialists in select EU countries.

Clinician comments

“I was pleased with the design of the PROPEL Contour sinus implant for patients with variable frontal sinus openings that are suffering from chronic rhinosinusitis,” said Prof. Dr. Jan Gosepath, Chairman, Department of Otolaryngology, Head and Neck Surgery, Helios HSK Wiesbaden and Medical Director, Helios Dr. Horst Schmidt Privatklinik Wiesbaden.

“With this implant, the surgically enlarged sinus opening can be maintained, and the steroid can be delivered directly to the site where it is needed most to improve postoperative outcomes. At 4-weeks follow-up, both patients showed excellent wound healing, which is what I like to see. Another benefit of the PROPEL Contour implant is that it does not need to be removed and will dissolve after approximately 4-6 weeks.”

Source: Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *